COVID-19 is a respiratory illness caused by the SARS-CoV-2 virus, ranging in severity from mild to critical. This category contains authorised pharmaceutical agents used for the treatment and supportive care of the infection, including antivirals and anti-inflammatory corticosteroids. These medications work by interfering with viral replication or managing the body's inflammatory response to the virus. We provide access to these regulated treatments to assist in the management and recovery from viral complications within a clinical framework.
COVID-19 is an infectious disease caused by the SARS-CoV-2 virus. It first appeared in late 2019 and quickly spread worldwide, prompting extensive medical research and public-health responses.
A variety of medicines have been used or authorised to help treat the infection and to provide supportive care. These medicines belong to different pharmacological groups, each addressing a particular aspect of the disease process.
The category includes antivirals that aim to stop viral replication, corticosteroids that reduce inflammation in the lungs, and immunomodulators that adjust the body’s immune response. Some agents originally developed for other conditions have also been investigated for their potential role in COVID-19 management.
This overview explains the conditions these medicines target, the main classes of drugs available, and the typical situations in which they are used.
Typical symptoms linked to these conditions are fever, persistent cough, shortness of breath, loss of taste or smell, and extreme fatigue. When severe, the illness can limit everyday activities, making simple tasks like walking or climbing stairs difficult.
The therapeutic approach to COVID-19 combines several strategies. Antivirals target the virus directly, aiming to lower the amount of virus in the body. Corticosteroids and immunomodulators focus on the host’s inflammatory response, helping to prevent lung damage when the disease becomes severe. Supportive care, such as oxygen therapy or hydration, works alongside these medicines to maintain overall health. Detailed pharmacology is covered on individual medication pages.
Antiviral: A drug that interferes with the virus’s ability to reproduce inside the body.
Corticosteroid: A medication that suppresses inflammation, often used when the lungs are inflamed.
Immunomodulator: A substance that modifies the activity of the immune system, aiming to reduce harmful over-reactions.
Cytokine storm: An excessive release of immune signalling proteins that can lead to widespread tissue damage.
Viral replication: The process by which a virus makes copies of itself inside host cells.
It groups together medicines that have been used or authorised to treat the infection itself or to manage the body’s response to the disease.
Antivirals interfere with the steps the virus uses to copy its genetic material, thereby reducing the amount of virus present in the body.
In severe disease, inflammation in the lungs can impair breathing; corticosteroids help dampen this inflammation, improving oxygen exchange.
It adjusts the immune system’s activity, aiming to prevent an overly aggressive response that can damage organs.
Yes, some agents, such as Molnupiravir, are taken orally, while others, like Dexamethasone, are commonly given by injection or intravenously in hospital settings.
The medicines listed are intended for treatment or supportive care after infection has been confirmed, not for prophylactic use.
Milder cases may be managed with oral antivirals, whereas hospitalised patients with significant lung involvement often receive corticosteroids and, where appropriate, immunomodulators.
Supportive care, such as oxygen therapy, fluid management, and monitoring, works together with drug treatment to maintain overall health while the body fights the infection.
Regulatory approvals and supply chains can vary, meaning some medicines may be authorised or more commonly used in the UK compared with other countries.
Early in the pandemic, repurposed drugs were explored extensively; as evidence accumulated, treatment guidelines evolved to prioritise therapies with demonstrated benefit, such as specific antivirals and corticosteroids.
